TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31519196

Group type: EXPERIMENTAL
Intervention: Low-dose chest CT (LDCT) and circulating tumor cells (CTC) search on a blood sample, followed by two additional screening rounds at one-year intervals.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Negative LDCT and presence of CTC.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Psychological impact of the screening strategy.
Number of subjects: 300
Study: 31519223

Group type: EXPERIMENTAL
Intervention: Non-genetic factors (demographic, clinical, and environmental)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Non-genetic factors
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Host genetics
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Previously reported associations between human genetic variants and specific taxa
Number of subjects: 1000
Study: 31519676

Group type: EXPERIMENTAL
Intervention: Community-based exercise (minimum of 60 min of mild-to-moderate intensity full body exercise twice weekly for a 12-week period)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Community-based exercise
Number of subjects: 2500
Study: 31519694

Group type: EXPERIMENTAL
Intervention: Machine learning-derived risk score (random survival forest model)
Number of subjects: 8756

Group type: COMPARATOR
Intervention: Cox-based method
Number of subjects: 8756
Study: 31519778

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT) with current stentriever/aspiration devices
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: High WMH burden
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: High WMH quartile
Number of subjects: 496
Study: 31520247

Group type: EXPERIMENTAL
Intervention: Patient-initiated PRO-based follow-up (open access telePRO)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Fixed-interval PRO-based follow-up (standard telePRO)
Number of subjects: 593
Study: 31520402

Group type: EXPERIMENTAL
Intervention: IOTA simple rules
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Pattern recognition
Number of subjects: 396
Study: 31520429

Group type: EXPERIMENTAL
Intervention: Telehealth family-focused melanoma preventive intervention
Number of subjects: 21
Study: 31520559

Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Baseline levels of eight potential biomarkers
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Pre-dose 3 levels of biomarkers
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Preliminary data
Number of subjects: 62
Study: 31521016

Group type: EXPERIMENTAL
Intervention: Acute Kidney Injury (AKI)
Number of subjects: 583

Group type: COMPARATOR
Intervention: No Acute Kidney Injury (non-AKI)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: AKI
Number of subjects: 583
Study: 31521128

Group type: EXPERIMENTAL
Intervention: CD8+ TIL-positive cases (n=205, 51.1%)
Number of subjects: 401

Group type: COMPARATOR
Intervention: CD68+ TAM-positive cases (n=184, 45.9%)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Positive CD8+ TIL and negative CD68+ TAM status
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (PAC)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) analysis
Number of subjects: 401
Study: 31521134

Group type: EXPERIMENTAL
Intervention: 3 cycles of FOLFIRINOX neoadjuvant chemotherapy followed by a short-course of carbon ion radiotherapy (CIRT)
Number of subjects: 0
Study: 31521574

Group type: EXPERIMENTAL
Intervention: CAVI
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: BA-PWV
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: CF-PWV
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Central augmentation index
Number of subjects: 501
Study: 31521672

Group type: EXPERIMENTAL
Intervention: Smaller cardiac ventricular size in patients with severe asthma
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Asthma exacerbation rate
Number of subjects: 233
Study: 31522581

Group type: EXPERIMENTAL
Intervention: Maternal serum amyloid A (mSAA) levels in women with PTB
Number of subjects: 58

Group type: COMPARATOR
Intervention: Maternal serum amyloid A (mSAA) levels in women who delivered at term (control group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Neonatal outcomes (not specified)
Number of subjects: 58
Study: 31522591

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting in women
Number of subjects: 932
Study: 31522619

Group type: EXPERIMENTAL
Intervention: Out-of-office blood pressure (BP) measurement
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Clinic blood pressure (BP) measurement
Number of subjects: 1262
Study: 31522983

Group type: EXPERIMENTAL
Intervention: T2FS-based radiomic model
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: T1FSGd-based radiomic model
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combined radiomic model
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: T2FS radiomic model combined into a nomogram with clinical staging
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: T1FSGd-based features
Number of subjects: 122
Study: 31523049

Group type: EXPERIMENTAL
Intervention: Treat-to-target low disease activity (T2T-LDA; 44-joint count Disease Activity Score ≤ 2.4)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Baseline features influencing adherence
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Anticitrullinated protein antibody/rheumatoid factor positivity
Number of subjects: 571
Study: 31523058

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 40
Study: 31523279

Group type: EXPERIMENTAL
Intervention: Triple therapy (clarithromycin, metronidazole, levofloxacin)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Bismuth quadruple therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Empirical amoxicillin-containing bismuth quadruple therapy
Number of subjects: 200
Study: 31523745

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31524342

Group type: EXPERIMENTAL
Intervention: ATX-101 (deoxycholic acid) 2 mg/cm2
Number of subjects: 165
Study: 31525136

Group type: EXPERIMENTAL
Intervention: Community exercise with inspiratory muscle training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31525774

Group type: EXPERIMENTAL
Intervention: Blood cultures obtained before initiation of antimicrobial treatment
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Blood cultures obtained within 120 minutes after initiation of antimicrobial treatment
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Other microbiological cultures
Number of subjects: 325
Study: 31526121

Group type: EXPERIMENTAL
Intervention: NMDAR1-abs seropositivity (IgM, IgA, and IgG)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: High titers of NMDAR1-abs (≥1:320)
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: NMDAR1-abs seropositivity
Number of subjects: 583
Study: 31526253

Group type: EXPERIMENTAL
Intervention: Left atrial function assessed with MRI-FT
Number of subjects: 1235

Group type: EXPERIMENTAL
Intervention: MRI-FT
Number of subjects: 1235
Study: 31526672

Group type: EXPERIMENTAL
Intervention: Spine SBRT
Number of subjects: 56
Study: 31526695

Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Conventional resections with unstandardised and limited lymph node dissection (control group)
Number of subjects: 1069
Study: 31526754

Group type: EXPERIMENTAL
Intervention: Emergency Room (ER) stratum
Number of subjects: 4509

Group type: EXPERIMENTAL
Intervention: Admission stratum
Number of subjects: 4509

Group type: EXPERIMENTAL
Intervention: Intensive Care Unit (ICU) stratum
Number of subjects: 4509

Group type: EXPERIMENTAL
Intervention: ICU stratum (moderate-to-severe TBI)
Number of subjects: 4509
Study: 31527168

Group type: EXPERIMENTAL
Intervention: INCB054329 (monotherapy)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: INCB057643 (monotherapy or in combination with standard-of-care)
Number of subjects: 203

Group type: COMPARATOR
Intervention: INCB054329
Number of subjects: 203

Group type: COMPARATOR
Intervention: INCB057643
Number of subjects: 203
Study: 31527689

Group type: EXPERIMENTAL
Intervention: Plasma EBV DNA-negative patients (0-20 copies/ml)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Plasma EBV DNA-positive patients (>20 copies/ml)
Number of subjects: 518
Study: 31527875

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) interruption
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Age 13 years and older
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Stunted children (height-for-age Z-scores <-2 SD)
Number of subjects: 873

Group type: EXPERIMENTAL
Intervention: Underweight children (weight-for-age Z-scores <-2 SD)
Number of subjects: 873
Study: 31528836

Group type: EXPERIMENTAL
Intervention: Almond snacking for 8 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Graham cracker snacking (isocaloric control)
Number of subjects: 73
Study: 31528838

Group type: EXPERIMENTAL
Intervention: DASH diet + Captopril (CAP) 25 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (CON) diet + Captopril (CAP) 25 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 44
Study: 31529018

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with a simultaneous integrated boost of radiotherapy dose (50.4 Gy to subclinical areas at risk and 63.0 Gy to the gross tumor and involved nodes, all given in 28 fractions) with concurrent docetaxel and capecitabine or fluorouracil
Number of subjects: 46

Group type: COMPARATOR
Intervention: Chemoradiotherapy with a simultaneous integrated boost
Number of subjects: 46
Study: 31529056

Group type: EXPERIMENTAL
Intervention: Higher concentrations of several-sized VLDL particles and medium- and small-sized HDL particles in women developing GDM (n = 82)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Higher concentrations of isoleucine and leucine, and GlycA in women developing GDM
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Higher concentration of small-sized HDL particles as a predictive marker for GDM
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Distinct early pregnancy metabolomic profile in women developing GDM
Number of subjects: 357
Study: 31529070

Group type: COMPARATOR
Intervention: Insulin tolerance test
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium depletion test (oral administration of 40 mg of furosemide under low sodium diet)
Number of subjects: 20
Study: 31529103

Group type: EXPERIMENTAL
Intervention: Single-port thoracoscopic sympathicotomy
Number of subjects: 8
Study: 31529136

Group type: EXPERIMENTAL
Intervention: Lower limb injections of abobotulinumtoxinA (1,000 U or 1,500 U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower and upper limb injections of abobotulinumtoxinA (1,000 U lower limb, 500 U upper limb)
Number of subjects: 0
Study: 31529145

Group type: EXPERIMENTAL
Intervention: CPAP-treated OSA patients with hypertension
Number of subjects: 41

Group type: COMPARATOR
Intervention: CPAP-treated OSA patients with normotension
Number of subjects: 41
Study: 31529318

Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 352
Study: 31529511

Group type: EXPERIMENTAL
Intervention: Very low energy diet
Number of subjects: 298

Group type: COMPARATOR
Intervention: Control (non-PCOS)
Number of subjects: 298
Study: 31530099

Group type: EXPERIMENTAL
Intervention: Artificial intelligence fitting for cochlear implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual fitting for cochlear implants
Number of subjects: 0
Study: 31530552

Group type: EXPERIMENTAL
Intervention: Circulating advanced glycation endproducts (AGEs)
Number of subjects: 555
Study: 31530565

Group type: EXPERIMENTAL
Intervention: Various cluster criteria for defining glaucomatous visual field abnormalities
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Definitions requiring abnormalities to be repeatable at the same location
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Visual field cluster criteria
Number of subjects: 384
Study: 31530660

Group type: EXPERIMENTAL
Intervention: Home-HIT intervention
Number of subjects: 11
Study: 31531798

Group type: EXPERIMENTAL
Intervention: CT colonography (CTC) followed by optical colonoscopy (OC)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Optical colonoscopy (OC)
Number of subjects: 223

Group type: COMPARATOR
Intervention: CT colonography (CTC)
Number of subjects: 223
Study: 31531823

Group type: EXPERIMENTAL
Intervention: Ischaemia-driven complete coronary revascularisation by percutaneous coronary intervention (PCI)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414
Study: 31531991

Group type: EXPERIMENTAL
Intervention: Menthol-flavoured quit smoking aid, electronically heated menthol-flavoured EC with 0% nicotine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Menthol-flavoured quit smoking aid, electronically heated menthol-flavoured EC with 5.4% nicotine
Number of subjects: 16
Study: 31532016

Group type: EXPERIMENTAL
Intervention: Maternal carotenoid levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal vitamin A levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal vitamin E levels
Number of subjects: 0
Study: 31532522

Group type: EXPERIMENTAL
Intervention: Leydig cell tumors (LCTs)
Number of subjects: 83
Study: 31532724

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks for up to 24 months
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 24
Study: 31532833

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (anti-PD-1), administered as part of a Phase II clinical trial, with biopsies taken at baseline and 15-21 days post-dose.
Number of subjects: 0
Study: 31533636

Group type: EXPERIMENTAL
Intervention: Pisando Fuerte (PF) intervention, 2-hour sessions delivered in Spanish over 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pisando Fuerte (PF) intervention
Number of subjects: 24
Study: 31533707

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 2
Study: 31533713

Group type: EXPERIMENTAL
Intervention: Cristal images teleimaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Before deployment of Cristal images (2015-2016)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: After deployment of Cristal images (2018-2019)
Number of subjects: 0
Study: 31533734

Group type: EXPERIMENTAL
Intervention: Condomless anal intercourse with non-steady partners
Number of subjects: 118
Study: 31533759

Group type: EXPERIMENTAL
Intervention: PDA surgical ligation
Number of subjects: 50
Study: 31533753

Group type: EXPERIMENTAL
Intervention: Breastfeeding (exclusive and non-exclusive)
Number of subjects: 6861

Group type: EXPERIMENTAL
Intervention: Breastfeeding (any 3 month period)
Number of subjects: 6861

Group type: EXPERIMENTAL
Intervention: Duration of exclusive breastfeeding
Number of subjects: 6861
Study: 31533771

Group type: EXPERIMENTAL
Intervention: Denosumab administered subcutaneously at 1 mg/kg body weight, dosage scheduled based on urinary deoxypyridinoline levels.
Number of subjects: 10
Study: 31533814

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) for 14 weeks
Number of subjects: 0
Study: 31533818

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 16
Study: 31533828

Group type: EXPERIMENTAL
Intervention: MyDiabetesPlan (an online decision aid)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Interprofessional shared decision-making (IP-SDM)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Usability assessment of MyDiabetesPlan
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Multi-component toolkit and implementation strategy
Number of subjects: 17
Study: 31533965

Group type: EXPERIMENTAL
Intervention: Quantitative fluorescence endoscopy
Number of subjects: 0
Study: 31533974

Group type: EXPERIMENTAL
Intervention: Fast MRI
Number of subjects: 299

Group type: COMPARATOR
Intervention: CT
Number of subjects: 299
Study: 31534013

Group type: EXPERIMENTAL
Intervention: AZD0156 (low doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD0156
Number of subjects: 0
Study: 31534192

Group type: EXPERIMENTAL
Intervention: G-CSF + plerixafor (G-CSF + P)
Number of subjects: 77
Study: 31534380

Group type: EXPERIMENTAL
Intervention: Doctor and pharmacy shopping (Shopping) for opioids
Number of subjects: 164923

Group type: COMPARATOR
Intervention: Insurance claims data
Number of subjects: 164923
Study: 31534773

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) twice a week for 5 weeks, consisting of 3-4 sets of 4-6 repetitions at ≥85% of 1RM in a squat exercise.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (CG) doing regular pre-season preparations.
Number of subjects: 33
Study: 31534782

Group type: EXPERIMENTAL
Intervention: Deep phenotyping through multiomics approaches
Number of subjects: 100
Study: 31535129

Group type: EXPERIMENTAL
Intervention: [13C10]retinyl acetate ingestion
Number of subjects: 3
Study: 31535135

Group type: EXPERIMENTAL
Intervention: Weight gainers (n = 36)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Weight stable group (n = 31)
Number of subjects: 67
Study: 31535207

Group type: EXPERIMENTAL
Intervention: Obese MS+ group
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Non-obese MS+ group
Number of subjects: 559

Group type: COMPARATOR
Intervention: Obese MS- group
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 559
Study: 31535597

Group type: EXPERIMENTAL
Intervention: Biochemically-verified cannabis abstinence
Number of subjects: 70
Study: 31536129

Group type: EXPERIMENTAL
Intervention: Single-port robotic surgical system
Number of subjects: 47
Study: 31536622

Group type: EXPERIMENTAL
Intervention: Cosyntropin-stimulated AVS
Number of subjects: 1625

Group type: COMPARATOR
Intervention: Unstimulated AVS
Number of subjects: 1625

Group type: COMPARATOR
Intervention: Post-adrenalectomy outcomes
Number of subjects: 1625
Study: 31537296

Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 0
Study: 31537446

Group type: EXPERIMENTAL
Intervention: Nonparametric tests for comparing immunological Reverse Cumulative distribution curves (RCDCs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rank-based tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCDCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonparametric tests
Number of subjects: 0
Study: 31537486

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (15 mg twice a day) on a continuous 28-day cycle
Number of subjects: 5
Study: 31537565

Group type: EXPERIMENTAL
Intervention: Lipid injectable emulsion (two doses)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Active control (no treatment)
Number of subjects: 64
Study: 31537687

Group type: EXPERIMENTAL
Intervention: Methylation-specific multiplex ligation-dependent probe amplification
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Methylation classifier based on nine promoters
Number of subjects: 24
Study: 31538078

Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg IV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline IV)
Number of subjects: 90
Study: 31538230

Group type: EXPERIMENTAL
Intervention: Lapatinib (750, 1000, 1250, or 1500 mg daily) plus Bortezomib (0.7, 1.0, 1.3, or 1.6 mg/m²)
Number of subjects: 0
Study: 31538605

Group type: EXPERIMENTAL
Intervention: Fitbit Alta HR
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Philips Respironics Actiwatch 2 (AW2) at medium setting (M10)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Philips Respironics Actiwatch 2 (AW2) at high motion threshold setting (H5)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fitbit
Number of subjects: 58
Study: 31538606

Group type: EXPERIMENTAL
Intervention: Neurometer current perception threshold (CPT) system at 2,000 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neurometer current perception threshold (CPT) system at 250 Hz
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neurometer current perception threshold (CPT) system at 5 Hz
Number of subjects: 32
Study: 31538815

Group type: EXPERIMENTAL
Intervention: Efficacy-toxicity design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dose-escalation followed by an expansion cohort
Number of subjects: 0

Group type: COMPARATOR
Intervention: DE-ECext
Number of subjects: 0
Study: 31538818

Group type: EXPERIMENTAL
Intervention: Daromun (intralesional immunocytokine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31538944

Group type: EXPERIMENTAL
Intervention: Future Patient Telerehabilitation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation program
Number of subjects: 0
Study: 31539467

Group type: EXPERIMENTAL
Intervention: Twice-daily Indacaterol/Glycopyrrolate (IND/GLY)
Number of subjects: 2038
Study: 31539582

Group type: EXPERIMENTAL
Intervention: Patient factors: elevated blood pressure (EBP), no familial history, single IA, active smoking
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Aneurysm factors: size≥5mm, narrow neck, irregular shape, ACA/Acom location
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Matched pair analysis risk factors: no familial history of aneurysm, narrow neck, active smoking, ACA/Acom location, irregular shape
Number of subjects: 1289
Study: 31539757

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) rs8187710 (ABCC2) and rs1801131 (MTHFR)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) rs3788007 (ABCG1) and rs4148943 (CHST3)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) rs2301159 (SLC10A2) and rs2470890 (CYP1A2)
Number of subjects: 59
Study: 31540306

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 0
Study: 31540339

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 31540745

Group type: EXPERIMENTAL
Intervention: IL4: rs2243250 genetic variant
Number of subjects: 359
Study: 31540834

Group type: EXPERIMENTAL
Intervention: Catheters placed for <3 days
Number of subjects: 127